目的：探讨针对2型糖尿病患者，观察选择甘精胰岛素+瑞格列奈完成治疗后获得的临床效果。方法选择该院2013年2月-2015年2月2型糖尿病患者70例。通过随机数表法完成2型糖尿病患者的随机分组。C2组(对照组35例)：临床选择胰岛素皮下注射的方法实施治疗。C1组(观察组35例)：临床选择甘精胰岛素+瑞格列奈进行治疗。对比两组2型糖尿病患者完成治疗后在相关指标方面表现出的差异。结果两组2型糖尿病患者完成治疗后，在HbAlc水平方面，C1组明显优于C2组2型糖尿病患者，差异有统计学意义(P<0.05)。结论针对2型糖尿病患者，临床选择甘精胰岛素+瑞格列奈进行治疗，针对患者的血糖稳定性能够有效进行维持，将患者的胰岛素用量能够有效降低，避免患者出现低血糖的情况，凸显两种药物联合治疗2型糖尿病疾病的临床价值。%Objective To observe the clinical effect of insulin glargine combined with repaglinide in the treatment of type 2 diabetes. Methods 70 cases with type 2 diabetes admitted in our hospital from February 2013 to February 2015 were se-lected and randomly divided into C1 group(observation group) and C2 group(control group) with 35 cases in each. C1 group was treated by insulin glargine and repaglinide, and C2 group was treated by subcutaneous injection of insulin. And the val-ue of relative parameters was compared between the two groups after treatment. Results After treatment, the level of HbAlc was much better in C1 group than that in C2 group (P<0.05). Conclusion For patients with type 2 diabetes, insulin glargine and repaglinide can effectively stabilize the level of blood glucose, reduce the dosage of insulin and avoid the incidence of hypoglycemia with significant clinical value.
展开▼
